Showing results (131-140 of 4,701) with videos related to
Sort By:
Pageof 471
Therapeutic Drug Monitoring|September 28, 2002
Simultaneous determination of rifampicin and efavirenz in plasmaMarta Boffito, John Tija, Helen E Reynolds, et al.Therapeutic Drug Monitoring|January 28, 2003
A preliminary study of the effect of fluoxetine treatment on the 2:16-alpha-hydroxyestrone ratio in young womenDiane S Thompson, Margaret A Kirshner, Thomas L Klug, et al.Therapeutic Drug Monitoring|January 28, 2003
Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedicationMarianne Gex-Fabry, Androniki E Balant-Gorgia, Luc P BalantTherapeutic Drug Monitoring|January 28, 2003
Pharmacokinetics of a single oral dose of baclofen in pediatric patients with gastroesophageal reflux diseaseH E Wiersma, C J van Boxtel, J J Butter, et al.Therapeutic Drug Monitoring|January 28, 2003
High-performance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasmaNadja E Schoemaker, Hilde Rosing, Sindy Jansen, et al.Therapeutic Drug Monitoring|January 1, 1979
Gas chromatographic method for the determination of valproic acid in human plasmaA E Hershey, J R Patton, K H DudleyTherapeutic Drug Monitoring|July 29, 2003
A new turbidometric digoxin immunoassay on the ADVIA 1650 analyzer is free from interference by spironolactone, potassium canrenoate, and their common metabolite canrenonePradip Datta, Amitava DasguptaTherapeutic Drug Monitoring|November 15, 2019
Nonparametric Population Pharmacokinetic Modeling of Isoniazid in Colombian Patients With TuberculosisCarlos A Rodriguez, Andres F Zuluaga, Michael N Neely, et al.Therapeutic Drug Monitoring|November 15, 2019
Comparison of the Area Under the Curve for Vancomycin Estimated Using Compartmental and Noncompartmental Methods in Adult Patients With Normal Renal FunctionRashmi V Shingde, Garry G Graham, Stephanie E Reuter, et al.Therapeutic Drug Monitoring|January 1, 1988
Detection of populations at risk and problem drugs during drug development and in pharmacotherapyP H HinderlingPageof 471